Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/607"
| Predicate | Value (sorted: none) |
|---|---|
| rdf:type | |
| rdf:type | |
| rdfs:label | |
| ?:Evidence_type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_value | |
| dc:creator | |
| dc:date |
"06/15/2009 15:11:07"
|
| ?:content |
""REMERONSolTab� (mirtazapine) Orally Disintegrating Tablets are rapidly and completely absorbed following oral administration and have a half-life of about 20�40 hours. Peak plasma concentrations are reached within about 2 hours following an oral dose. The presence of food in the stomach has a minimal effect on both the rate and extent of absorption and does not require a dosage adjustment. REMERONSolTab� Orally Disintegrating Tablets are bioequivalent to REMERON� (mirtazapine) Tablets."
NOTE: various mirtazapine product labels indicate that there is no difference in fraction absorbed between the rapidly disintegrating and tablet formulations."
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ mirtazapine_fraction_absorbed_continuous_value, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1998 }